Agilon Health Elects New Directors at Annual Meeting

Agilon Health ( (AGL) ) has shared an announcement.

On May 28, 2025, Agilon Health held its annual meeting of stockholders where Silvana Battaglia and Sharad Mansukani, M.D. were elected as Class I directors to serve until the 2028 annual meeting. Additionally, stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for 2025 and approved, on a non-binding basis, the executive compensation for the company’s named officers.

The most recent analyst rating on (AGL) stock is a Sell with a $2.40 price target. To see the full list of analyst forecasts on Agilon Health stock, see the AGL Stock Forecast page.

Spark’s Take on AGL Stock

According to Spark, TipRanks’ AI Analyst, AGL is a Neutral.

Agilon Health’s overall stock score of 45 reflects significant financial challenges, weak technical indicators, and concerning valuation metrics. Despite some potential for future improvement highlighted in the earnings call, the company’s current profitability issues and cash flow struggles weigh heavily on its outlook. The stock’s underperformance and lack of dividends further reduce its attractiveness.

To see Spark’s full report on AGL stock, click here.

More about Agilon Health

Agilon Health operates in the healthcare industry, focusing on providing value-based care solutions for primary care physicians. The company partners with physician groups to enhance patient care and improve healthcare outcomes.

Average Trading Volume: 5,918,765

Technical Sentiment Signal: Sell

Current Market Cap: $923.1M

Find detailed analytics on AGL stock on TipRanks’ Stock Analysis page.